Featured Research

from universities, journals, and other organizations

Genomic study reveals why children in remission from rheumatoid arthritis often experience recurrences

Date:
August 29, 2013
Source:
University at Buffalo
Summary:
A new study published today in Arthritis Research & Therapy provides the first genomic characterization of remission in juvenile rheumatoid arthritis patients.

More children with juvenile rheumatoid arthritis are experiencing remission of their symptoms, thanks to new biological therapies, but the remission is not well-understood. A new study published today in Arthritis Research & Therapy provides the first genomic characterization of remission in juvenile rheumatoid arthritis patients.

Related Articles


"It turns out that even though these children in remission appear to be perfectly normal and symptom-free, their immune systems are still perturbed," says James N. Jarvis, MD, clinical professor of pediatrics in the University at Buffalo School of Medicine and Biomedical Sciences and the study's lead author.

The study notes that 35-50 percent of children with juvenile rheumatoid arthritis achieve remission while being treated with the standard treatments, methotrexate or methotrexate in combination with biopharmaceuticals.

"Our study provides some insight into why so many children in remission experience disease flares even when their disease has been stable for weeks or months, and why 50 percent of children who try to come off medication experience disease flares within two to six months," Jarvis says.

The research was conducted at the University of Oklahoma Health Sciences Center by Jarvis and co-authors, and was supported by the National Institutes of Health, the Oklahoma Center for the Advancement of Science and Technology and the Arthritis Foundation, which continues to fund Jarvis' research in this area. Some members of the team, including Jarvis, now work at UB's Clinical and Translational Research Center (CTRC).

The study compared gene expression profiles from two independent cohorts of 14 patients each, all in remission from juvenile rheumatoid arthritis, to those of 15 healthy controls. The patients were on two different medication regimens. Patients were followed every two to three months for at least a year.

"Remission, of course, is our goal," says Jarvis. "I like to say it's hard to get somewhere when you don't know where 'somewhere' is. My lab is trying to build a 'genomic roadmap' for what remission is and exactly how we get there. That way, we can find a way to get these children into remission more quickly and for longer periods."

The new study confirms preliminary research by Jarvis, suggesting that remission experienced by patients with juvenile rheumatoid arthritis on medication is not a "return to normal" but is, instead, a distinct biologic state. The study finds that this distinct biologic state results from pro-inflammatory responses being counter-balanced by anti-inflammatory responses caused by gene expression changes that medication induces.

A key finding is that remission in these patients depends on HNF4a, a transcription factor that binds to DNA, acting as an "on" or "off" switch for gene expression. Until now, Jarvis says, HNF4a was seen only as a regulator of metabolism in liver and pancreatic cells.

"Our research suggests that HNF4a is one of what we suspect is a group of master switches that regulate therapeutic response," explains Jarvis.

The study found that more than 200 genes in white blood cells were expressed differently in children taking a combination treatment of methotrexate and a biological drug called etanercept compared to healthy controls. Some of those differentially expressed genes have been shown to bind to HNF4a.

Jarvis notes that the findings will make possible future studies that will identify specific biomarkers involved in how individual patients respond to specific therapies.

"This is a first step toward the goal of identifying biomarkers that will ultimately allow clinicians to personalize treatment by predicting which patients will respond best to which therapies," he says.

He adds that this kind of research will depend on longitudinal studies that monitor gene expression before, during and after treatment. Jarvis currently is principal investigator on a $1.2 million NIH grant to study microarray-based biomarkers in juvenile idiopathic arthritis. He also is studying the role of epigenetics in juvenile rheumatoid arthritis supported by several foundation grants.

Co-authors with Jarvis on the study are Kaiyu Jiang and Yanmin Chen, formerly of the University of Oklahoma Health Sciences Center, now at UB's CTRC, and Mark Barton Frank and Jeannette Osban of the Oklahoma Medical Research Foundation.


Story Source:

The above story is based on materials provided by University at Buffalo. The original article was written by Ellen Goldbaum. Note: Materials may be edited for content and length.


Journal Reference:

  1. Kaiyu Jiang, M. Barton Frank, Yanmin Chen, Jeanette Osban, James N. Jarvis. Genomic Characterization of Remission in Juvenile Idiopathic Arthritis. Arthritis Research & Therapy, 2013; 15 (4): R100 DOI: 10.1186/ar4280

Cite This Page:

University at Buffalo. "Genomic study reveals why children in remission from rheumatoid arthritis often experience recurrences." ScienceDaily. ScienceDaily, 29 August 2013. <www.sciencedaily.com/releases/2013/08/130829214250.htm>.
University at Buffalo. (2013, August 29). Genomic study reveals why children in remission from rheumatoid arthritis often experience recurrences. ScienceDaily. Retrieved November 23, 2014 from www.sciencedaily.com/releases/2013/08/130829214250.htm
University at Buffalo. "Genomic study reveals why children in remission from rheumatoid arthritis often experience recurrences." ScienceDaily. www.sciencedaily.com/releases/2013/08/130829214250.htm (accessed November 23, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Sunday, November 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

WFP: Ebola Risks Heightened Among Women Throughout Africa

WFP: Ebola Risks Heightened Among Women Throughout Africa

AFP (Nov. 21, 2014) Having children has always been a frightening prospect in Sierra Leone, the world's most dangerous place to give birth, but Ebola has presented an alarming new threat for expectant mothers. Duration: 00:37 Video provided by AFP
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com
Raw: Paralyzed Marine Walks With Robotic Braces

Raw: Paralyzed Marine Walks With Robotic Braces

AP (Nov. 21, 2014) Marine Corps officials say a special operations officer left paralyzed by a sniper's bullet in Afghanistan walked using robotic leg braces in a ceremony to award him a Bronze Star. (Nov. 21) Video provided by AP
Powered by NewsLook.com
Milestone Birthdays Can Bring Existential Crisis, Study Says

Milestone Birthdays Can Bring Existential Crisis, Study Says

Newsy (Nov. 21, 2014) Researchers find that as people approach new decades in their lives they make bigger life decisions. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins